Home
Scholarly Works
TAFRO syndrome successfully treated with...
Journal article

TAFRO syndrome successfully treated with tocilizumab: A case report and systematic review

Abstract

Thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (TAFRO) syndrome is considered as a unique clinicopathologic variant of multicentric Castleman's disease and is recently reported in Japan. This entity represents a severe inflammatory state leading to organ failures such as severe liver dysfunction seen in our case, and can be treated by immunosuppressive agents, steroids, and cyclosporine shown in several case reports. A systematic review and our case suggest the potential utility of tocilizumab as a treatment for TAFRO syndrome.

Authors

Sakai K; Maeda T; Kuriyama A; Shimada N; Notohara K; Ueda Y

Journal

Modern Rheumatology, Vol. 28, No. 3, pp. 564–569

Publisher

Oxford University Press (OUP)

Publication Date

May 4, 2018

DOI

10.3109/14397595.2015.1120389

ISSN

1439-7595

Contact the Experts team